PACTR202102588777597Other3 期
A Multi-Center, Open- Label, Randomized, Controlled Clinical Trial of the Efficacy of Ivermectin for the Treatment and Prophylaxis of COVID-19
AGOS STATE MINISTRY OF HEALTH0 个研究点目标入组 240 人开始时间: 2021年2月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- Other
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •(1) Provide written informed consent prior to initiation of any study procedures
- •(2) Understand and agree to comply with planned study procedures
- •(3) Agree to the collection of oropharyngeal swabs and venous blood per protocol
- •(4) Be male or non-pregnant female adult =18 years of age at time of enrolment
- •(5) Have laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen no more than 72 hours prior to randomisation.
排除标准
- •1. American Society of Anaesthesiologists (ASA) class 3 and above.
- •2. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30)
- •3. Pregnant or breast feeding.
- •4. Anticipated transfer to another facility which is not a study site within 72 hours.
- •5. Participants with known haematological diseases (G6PD deficiency)
- •6. Participants with chronic liver and kidney disease and reaching end-stage.
- •7. Participants with arrhythmia and chronic heart disease.
- •8. Participants known to have retinal disease or hearing loss.
- •9. Participants known to have a mental illness.
- •10. Skin disorders (including rash, dermatitis, psoriasis).
- •11. Allergy to Ivermectin or its analogues.
研究者
相似试验
尚未招募
3 期
Efficacy of Ivermectin for the Treatment and Prophylaxis of COVID-19 diseaseCoronavirus disease 2019PACTR202102535686338agos State Ministry of Health240
进行中（未招募）
1 期
An international study at different study sites testing the safety and tolerability of a drug, lucinactant, which is to be inhaled as a means to treat breathing problems in babies born prematurely in the 26 to 28 weeks.Respiratory Distress Syndrome (RDS)MedDRA version: 19.1Level: LLTClassification code 10021735Term: Infant respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: LLTClassification code 10038690Term: Respiratory distress syndrome (neonatal)System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 19.1Level: PTClassification code 10028974Term: Neonatal respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-005624-26-PLWindtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.)64
进行中（未招募）
1 期
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with InhibitorsHaemophilia A with inhibitorsHaemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000011928MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000011929EUCTR2016-000510-30-GRovo Nordisk A/S26
进行中（未招募）
1 期
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with InhibitorsHaemophilia A with inhibitorsHaemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2016-000510-30-ITOVO NORDISK. S.P.A.26
进行中（未招募）
1 期
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients with InhibitorsHaemophilia A with inhibitorsHaemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2016-000510-30-HRovo Nordisk A/S26